Latest Period
Q4 2025
Security Snapshot
Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (UNCY) Institutional Ownership
CUSIP: 90466Y202
13F Institutional Holders and Ownership History from Q2 2025 to Q1 2026
Institutions Reporting
34
Shares (Excl. Options)
8,144,623
Price
$5.77
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- UNCY on Nasdaq
- Shares outstanding
- 24,093,727
- Price per share
- $6.45
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 8,144,623
- Total reported value
- $47,021,122
- % of total 13F portfolios
- 0%
- Share change
- +1,782,956
- Value change
- +$10,346,527
- Number of holders
- 34
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- UNCY - Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 90466Y202.
- 34 institutions reported positions in Q4 2025.
- 7 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 34 to 26 between Q4 2025 and Q1 2026.
- Reported value moved from $47,021,122 to $12,181,084.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 34 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 90466Y202?
CUSIP 90466Y202 identifies UNCY - Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 90466Y202:
Significant Owners of Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (UNCY) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 10% | $26,579,323 | 6,096,175 | Vivo Opportunity Fund Holdings, L.P. | 30 Sep 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $14,001,588 | +$2,495,038 | 2,385,279 | +22% | RA Capital Management, L.P. | 31 Dec 2025 |
| Nantahala Capital Management, LLC | 10% | $13,389,705 | 2,281,040 | Nantahala Capital Management, LLC | 31 Dec 2025 | |||
| BIOTECHNOLOGY VALUE FUND L P | 10% | $7,439,864 | 1,417,117 | BVF PARTNERS L P/IL | 30 Jun 2025 | |||
| INTEGRATED CORE STRATEGIES (US) LLC | 5.5% | $6,555,209 | 1,172,667 | Integrated Core Strategies (US) LLC | 16 Jan 2026 | |||
| Octagon Capital Advisors LP | 4.7% | -17% | $5,870,000 | 1,000,000 | 0% | Octagon Capital Advisors LP | 31 Dec 2025 | |
| GREAT POINT PARTNERS LLC | 4.5% | -29% | $3,472,993 | 796,558 | 0% | Great Point Partners, LLC | 30 Sep 2025 |
As of 31 Dec 2025, 34 institutional investors reported holding 8,144,623 shares of Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (UNCY). This represents 34% of the company’s total 24,093,727 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (UNCY) together control 34% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 7.4% | 1,789,916 | 0% | 0.67% | $10,327,815 |
| MILLENNIUM MANAGEMENT LLC | 4.2% | 1,014,843 | 0% | $5,855,644 | |
| Octagon Capital Advisors LP | 4.2% | 1,000,000 | 0% | 0.72% | $5,770,000 |
| Nantahala Capital Management, LLC | 3.9% | 939,202 | 0% | 0.32% | $5,419,196 |
| GREAT POINT PARTNERS LLC | 3.3% | 796,558 | 0% | 1.5% | $4,596,140 |
| VANGUARD GROUP INC | 3.3% | 788,587 | +20% | 0% | $4,550,147 |
| Logos Global Management LP | 2% | 473,563 | 0% | 0.18% | $2,732,459 |
| CITADEL ADVISORS LLC | 1.1% | 258,301 | +520% | 0% | $1,490,397 |
| CANTOR FITZGERALD, L. P. | 0.83% | 200,000 | 0.03% | $1,154,000 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.71% | 171,290 | +36% | 0% | $989,213 |
| BNP PARIBAS FINANCIAL MARKETS | 0.41% | 99,742 | 0% | 0% | $575,511 |
| Dauntless Investment Group, LLC | 0.37% | 89,415 | 2.1% | $515,925 | |
| OMERS ADMINISTRATION Corp | 0.32% | 78,200 | 0% | $451,214 | |
| STATE STREET CORP | 0.27% | 65,227 | +19% | 0% | $376,360 |
| ACUTA CAPITAL PARTNERS, LLC | 0.25% | 59,985 | 0% | 0.23% | $346,113 |
| Squarepoint Ops LLC | 0.23% | 55,305 | -53% | 0% | $319,110 |
| MORGAN STANLEY | 0.19% | 46,584 | +339% | 0% | $268,790 |
| Quadrature Capital Ltd | 0.16% | 39,114 | 0% | $225,688 | |
| BlackRock, Inc. | 0.15% | 36,355 | 0% | 0% | $209,768 |
| NORTHERN TRUST CORP | 0.15% | 35,937 | +9.9% | 0% | $207,356 |
| XTX Topco Ltd | 0.15% | 35,405 | -6.4% | 0.01% | $204,287 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.1% | 24,931 | 0% | $143,852 | |
| Chicago Partners Investment Group LLC | 0.09% | 22,413 | -17% | 0% | $155,098 |
| UBS Group AG | 0.08% | 19,905 | +266% | 0% | $114,852 |
| Tower Research Capital LLC (TRC) | 0.01% | 1,920 | 0% | $11,078 |
Institutional Holders of Unicycive Therapeutics, Inc. - Common Stock, $0.001 par value per share (UNCY) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 1,847,642 | $12,181,084 | +$3,959,615 | $6.58 | 26 |
| 2025 Q4 | 8,144,623 | $47,021,122 | +$10,346,527 | $5.77 | 34 |
| 2025 Q3 | 6,285,927 | $27,416,349 | +$4,969,291 | $4.36 | 30 |
| 2025 Q2 | 5,144,083 | $24,616,897 | +$24,616,897 | $4.77 | 19 |